Molecule Name |
DB08827
|
DrugBank Groups |
Approved
|
Cluster No |
990
|
Smiles |
FC(F)(F)C6(=CC=C(C5(=C(C(=O)NC4(CCN(CCCCC2(C1(=C(C=CC=C1)C3(=C2C=CC=C3)))(C(=O)NCC(F)(F)F))CC4))C=CC=C5))C=C6)
|
Download |
mol2, pdbqt
|
TPSA |
61,44
|
Non-H Atoms |
50
|
Non-C/H Atoms |
11
|
Metal-Atoms |
0
|
Electronegative Atoms |
11
|
Stereo Centers |
0
|
Rotatable Bonds |
12
|
Rings Closures |
6
|
Small Rings |
6
|
Aromatic Rings |
4
|
Aromatic Atoms |
24
|
sp3-Atoms |
14
|
Symmetric atoms |
14
|
cLogS |
-9,194
|
MW |
693,73
|
cLogP |
8,518
|
HBA |
5
|
HBD |
2
|
Ro5 violations |
2
|
Druglikeness |
0,005857
|
DrugScore |
3,84151143316772E-02
|
Mutagenic |
high
|
Tumorigenic |
high
|
Reproductive Effective |
none
|
Irritant |
none
|
Blood-Brain Barrier |
BBB+
|
Human Intestinal Absorption |
HIA+
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor 2 |
Inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-4,0968
|
Caco-2 Permeability 2 |
0,746
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Inhibitor
|
CYP450 2C19 Inhibitor |
Inhibitor
|
CYP450 3A4 Inhibitor |
Inhibitor
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
1,3643
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,5661
|
Honey Bee Toxicity |
Low HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,7151
|
Carcinogenicity (Three-class) |
Non-required
|